Illustrative image – not actual.
Chennai-based Orchid Pharma will invest about Rs 600 crore in capex for its upcoming new manufacturing plant in Jammu. The company’s wholly-owned subsidiary, Orchid BioPharma, has been approved under the PLI scheme to manufacture 7-aminocephalosporanic acid (7-ACA) with a committed capacity of 1,000 tpa. The approval will help the company in backward integration of raw materials and lowering sourcing dependency.
7-ACA is the core chemical structure for the synthesis of cephalosporin antibiotics and intermediates, and earlier this year, Orchid Bio Pharma has signed an MoU with an overseas technology provider for in-licensing of the product.
The pharmaceutical company manufactures solutions including active pharmaceutical ingredients (APIs) and finished dosage forms from its Alathur plant near Chennai. Further, apart from its four sterile blocks operating at 90 to 95 percent capacity, a fifth one is scheduled to be operational from June, 2023, which will add nearly 25 percent capacity to its sterile products.
